Myelodysplastic syndrome - lenalidomide

The PBS subsidises lenalidomide for patients with myelodysplastic syndrome.

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lenalidomide under the National Health Act 1953, section 100 for patients with myelodysplastic syndrome.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lenalidomide.

Section 100 arrangements

Lenalidomide

This item is only PBS-subsidised for day non-admitted patients, day admitted patients or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS-subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for initial or first continuing treatment

Patients receiving lenalidomide under this PBS listing must be registered in the i-access risk management program.

Applications for initial or first continuing authority approval to prescribe PBS-subsidised lenalidomide to treat myelodysplastic syndrome can be made either in:

All written applications must include the completed:

Applying for subsequent continuing treatment

Applications for subsequent continuing authority approval to prescribe PBS-subsidised lenalidomide to treat myelodysplastic syndrome can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 July 2022